AnaptysBio, Inc.

Common Stock · USD · NASDAQ

ANABT212

Price

$57.79

-0.16%

Cap

$125.07B

Earnings

—

30d Trend

-13.0%

0HFQ

Loading chart data...

0 days · % change from startPowered by Brain47

VolatilityHigh

69% annualised over 90 days

BRAIN47 SIGNAL

MODERATE

Risk Level73

Quality46

Momentum83

Technical59

Fundamentals38

Raw weighted: 52×Macro 0.99 (−1%)=51

RISK

73/100

90d Volatility

69.4%High

ATR %

11.2%High daily moves

Max Drawdown (1Y)

-28.1%Normal

QUALITY

46/100

ROE (avg)

-35.6%Negative

Piotroski F-Score

5/9Average

Accruals

-9.0%Cash earnings

MOMENTUM

83/100

12-1M Momentum

+287.7%Strong uptrend

6-1M Momentum

+113.9%Positive

1M Return

-8.5%Recent pullback

Earnings Surprise

+71.7%Strong beat

Relative Strength

+0.4% vs sectorIn-line

TECHNICAL

59/100

RSI (14)

45.1Neutral

Price vs SMA200

+72.7%Bullish trend

MACD

-1.58Bearish momentum

Bollinger Band

12%Near lower band

SMA Cross

Death CrossDeath Cross

Trend Quality (KER)

0.176Noisy/choppy

FUNDAMENTALS

38/100

EV/EBIT

34.5Expensive

P/FCF

96.5Expensive

P/S

8.1Expensive

Shareholder Yield

3.6%Moderate

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months41

3-12 months ★83

1-5+ years49

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate AnaptysBio, Inc. at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 83/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

-8.5%

3 MONTHS

+55.4%

12 MONTHS

+279.1%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (83) and Technical (59) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 69%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.

growthScore: 51/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.